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Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic
leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based ﬁrst line
therapy. One hundred eleven patients affected by locally advanced andmetastatic soft tissue sarcomawere selected. PML expression was
evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML
immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based ﬁrst
line therapy. PML expression was signiﬁcantly reduced in synovial sarcomas (P< 0.0001), in myoﬁbroblastic sarcomas (P< 0.0001),
angiosarcomas (P< 0.0001), in leiomyosarcomas (P¼ 0.003), in mixoid liposarcomas (P< 0.0001), and in dedifferentiated liposarcomas
(P< 0.0001). No signiﬁcant difference was found for pleomorphic sarcoma [31.8 (95% CI: 16.7–41.0); P¼ 0.21]. and pleomorphic
liposarcomas (P¼ 0.51). Loss of PML expression was found to be statistically correlated with TTP (P< 0.0001), median duration of
response (P¼ 0.007), and OS (P¼ 0.02). No correlation was observed between PML expression and treatment efﬁcacy. PML IHC
expression is down-regulated in synovial sarcomas, myoﬁbroblastic sarcomas, angiosarcomas, liposarcoma, and leiomyosarcomas and its
expression correlated with prognosis.
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PML is known to be involved in the pathogenesis of acute
promyelocytic leukaemia, which is characterized by the t(15;17)
traslocation that brings to the juxtaposition between PML gene,
located in 15q22 locus, and the gene encoding for the retinoid
acid receptor a, on chromosome 17. The two fusion proteins
deriving from the t(15;17) traslocation (PML-RARa and RARa-
PML) lead to a differentiation blockage and a shorter survival of
myeloid precursors (Melnick and Licht, 1999).
PML gene consists of nine exons from which, through
alternative splicing, seven different isoforms originate, both
nuclear (PML I, II, III, IV, V, VI) and citoplasmatic (VII) (Salomoni
and Bellodi, 2007). PML nuclear isoforms, marked by the
presence of nuclear localization signal encoded in exon 6, can
both localize in nucleoplasmor into complexmultiproteinaceus
structures called PML nuclear bodies (PML-NBs). PML-NBs
recognize both constitutive elements, represented by high
ordered PMLmultimers and S100 monomers, and components
which provisionally place in PML-NBs and interact with PML
itself such as p53, DAXX, c-Jun, pRB, mTOR (Weidtkamp-
Peters et al., 2008). PML-NBs formation and the interactions
between PML and its different protein partners become
possible thanks to post-traslational modiﬁcations among which
small ubiquitin-like modiﬁers (SUMO) emerged to be
particularly relevant (Shen et al., 2006).
Although today some of the biological aspects of PML action
into PML-NBs are still not clear, different studies underline the
importance of PML in the regulation of apoptosis, cellular
proliferation and senescence, pointing out a possible
involvement of this oncosuppressor in the pathogenesis of
different non-hematological neplasms.
Soft tissue sarcomas are deﬁned as a group of rare tumors
originating from non-epithelial extraskeletal tissues, including
muscle, fat and ﬁbrous structures, deriving mainly from
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embryonic mesoderm with a partial neuroectodermal
contribution. These tumors can arise anywhere in the body
(although limb, limb girdle, and abdomen are the most frequent
sites) and appear to be extremely heterogeneous, including
more than 50 different histotypes (Clark et al., 2005). Regarding
epidemiologic aspects, soft tissue sarcomas account for<1% of
all human tumors in the adult, with an annual incidence of
10,390 new cases in United States. The median age at the
diagnosis is 57 years and the onset of these tumors in the III–IV
decade is not rare (Ries et al., 2007).
The treatment of soft tissue sarcomas consists of a
multimodal approach deriving from the integration of surgery,
radiotherapy, and standard chemotherapy. Themanagement of
locally advanced and metastatic soft tissue sarcomas is today
founded on standard chemotherapy. Ifosfamide plus
doxorubicin-based regimens are routinely used in this setting as
ﬁrst line treatment.Unfortunately, despite the advances done in
the last 10 yearswith the introductionof new target drugs, up to
date soft tissue sarcomas becomemetastatic into 2 years in 80%
of patients, with a 5-years overall survival (OS) of 25–30% (Ries
et al., 2007). Given these data, the identiﬁcation of prognostic
elements and reliable factors predicting the efﬁcacy of alkylating
agents/antracycline-based therapy appears necessary, in order
to better identify those patients who could beneﬁt from a
standard chemotherapy and those who require alternative
approaches.
Aim of this retrospective study was to assess PML
immunohistochemical expression in six different subtypes of
soft tissue sarcoma (synovial sarcoma, myoﬁbroblastic
sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma,
pleomorphic sarcoma) and evaluate PML down-regulation as a
predictive factor predicting of resistance to alkylating agents/
antracycline-based ﬁrst line therapy in patients affected by
locally advanced and metastatic soft tissue sarcomas.
Materials and Methods
Tumor specimen acquisition and histological examination
Samples sources. One hundred eleven cases diagnosed between
September 2007 and November 2008 have been collected from the
records of Pathology Departments of Regional Hospital of Treviso,
Campus Bio-Medico of Rome and University of Palermo. Only cases
with available parafﬁn blocks were selected. All the clinical data were
reviewed and a reclassiﬁcation of all the cases according to the new
criteria for diagnosis (WHO) was performed.
Assembly of TMA. A hematoxylin- and eosin-stained (H&E)
section from each primary tumor was prepared and areas of
representative non-necrotic neoplasm circled on coverslip. Using a
Beecher Instrument (Silver Spring, MD), TMAs were constructed
introducing three cores of 1mmdiameter of selected tumor region and
two cores of corresponding normal tissue from each case. Following
tissue microarray (TMA) construction, H&E stained section of the
TMA recipient block was prepared and reviewed to conﬁrm the
presence of intact neoplasm. Sections of 5mmwere prepared in order
to perform H&E stain as well as IHC staining.
Immunohistochemical analysis. IHC was performed by the
streptavidin–biotin method. Endogenous peroxidase in the sections
was blocked by incubating them in 3% hydrogen peroxide. A rabbit
polyclonal antibody against PML protein (clone PG-M3; Santa Cruz
Biotecnology, Inc, Santa Cruz, CA) was used at 1:50 dilution. This
antibody has been used and validated previously by our group and by
others (Lee et al., 2007; Vincenzi et al., 2009). Sections were incubated
with LSAB2 (Dakocytomation). 3-3’-diaminobenzidine (DAB) was
used for color development and hematoxylin was used for
counterstaining. Negative control TMA slides processed without
primary antibody were prepared. Slides were examined without
knowledge of the corresponding clinico-pathologic data.
Immunostaining was considered positive if appropriate brown staining
was seen in cellular nucleus. PMLexpressionwas established calculating
the percentage of nuclear immunoreactive cells out of the total cells
counted. The immunostaining evaluation was conducted by two
different pathologist, both of which were not aware of patients clinical
data. In terms of PML IHC results, all cases were classiﬁed as follows:
complete loss (nuclear immunoreactivity in<10%of tumor cells), focal
positivity (in 10% but <50%), and diffuse positivity (in 50%), as
previously reported by Lee et al. (2007).
Statistical analysis
Descriptive analysis was performed using median values and 95%
conﬁdence interval (CI). Differences between tumor tissue and
normal surrounding tissue were assessed by using the Wilcoxon’s
test for non-parametric-dependent continuous variables.
SPSS software (version 17.00; SPSS, Chicago, IL) was used for
statistical analysis. A P-value of <0.05 was considered to indicate
statistical signiﬁcance.
The time-to-progression (TTP) analysis was calculated as the
period from the date of starting the treatment to the ﬁrst
observation of disease progression or to death from any cause
within 60 days after the start of treatment or the most recent
tumor assessment. The OS time was calculated as the period from
the date of starting treatment until death from any cause or until
the date of the last follow-up, at which point data were censored.
TTP andOSwere both determined by Kaplan–Meier product-limit
method (Kaplan and Meier, 1958). Stratiﬁed permutation tests
were carried out to explore the association between tumor
response and PML down-regulation. The differences in terms of
TTP and OS according to the presence of PML down-regulation
were evaluated by the log-rank test (Peto et al., 1977). The Cox
proportional hazardsmodelwas applied to themultivariate survival
analysis (Cox, 1972).
Results
PML immunohistochemical expression in
soft tissue sarcomas
PML IHC expression was evaluated in six different subtypes of
soft tissue sarcoma (synovial sarcoma, myoﬁbroblastic
sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma,
pleomorphic sarcoma) and in the corresponding normal tissue
samples (Table 1). PML IHC expression resulted focally or
completely lost inmost of the pathological samples (Fig. 1), with
the exception of pleomorphic sarcoma and pleomorphic
liposarcoma: particularly, no angiosarcoma, synovial sarcoma,
or mixoid liposarcoma samples showed a diffuse PML positivity
(Table 2).
PML expression was signiﬁcantly reduced in synovial
sarcoma specimens, with a median expression percentage of
10.3% (95% CI: 3.98–21.06) and a value of 40.8% (95% CI:
26.87–54.5; P< 0.0001) in the corresponding normal tissue.
Furthermore, a signiﬁcantly lower PML median expression was
found in myoﬁbroblastic sarcoma [18.5% (95% CI: 12.5–26.7)
vs. 41.7% (95% CI: 24.9–58.7); P< 0.0001] and in angiosarcoma
[15.8% (95% CI: 4.7–20.6) vs. 39.0% (95% CI: 24.8–58.30;
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P< 0.0001] when compared with the normal tissue samples. A
statistically signiﬁcant difference was also observed between
PML median expression in leiomyosarcoma and normal tissue
control (21% [95%CI: 10.5-31.2] vs. 40.5% [95% CI: 26.9-61.8];
P¼ 0.003).
On the contrary, no signiﬁcant difference in median PML
expressionwas found between pleomorphic sarcoma specimen
[31.8 (95%CI: 16.7–41.0)] and normal tissue control [38.7 (95%
CI: 24.9–55.3); P¼ 0.21].
As for liposarcoma, PML median expression appeared
signiﬁcantly reduced in mixoid liposarcoma [11.4% (95% CI:
6.9–18.5) vs. 42.7% (95% CI: 26.0–52.0); P< 0.0001] and in
dedifferentiated liposarcoma [17.6% (95% CI: 11.5–29.8) vs.
39.8% (95% CI: 24.6–58.2); P< 0.0001], while no signiﬁcant
differencewas detected between pleomorphic liposarcoma and
normal tissue specimens [36.0 (95%CI: 18.8–46.1) vs. 38.6 (95%
CI: 23.4–53.8); P¼ 0.51].
Correlation between PML expression and
treatment efﬁcacy
Patients with complete loss of PML expression showed a
median TTP of 3.50 months (95% CI: 1.78–4.93), compared
with 7.00 months (95% CI: 3.51–12.11) in those with a focally
and diffuse PML positivity (P< 0.0001). A statistically signiﬁcant
difference was observed also in terms of median duration of
response, which resulted 1.8 months (95% CI: 1.01–5.80) in
patients with complete loss of PML expression and 7.5 months
(95%CI: 4.33–10.34) in thosewith partial PML loss. (P¼ 0.007).
Finally, overall survial (OS)was found to be signiﬁcantly lower in
patients with complete loss of PML when compared with those
having a focally and diffuse positivity [9.8 months (95%CI: 5.67–
18.80) vs. 17.50 months (95% CI: 11.50–23.30); P¼ 0.02]. All
these data are summarized in Table 3 and Kaplan–Meier curves
are shown in Figure 2.
Fig. 1. PML immunohistochemical expression innormal tissue (AandC)and its down-regulation in soft tissue sarcomas (BandD). [Colorﬁgure
can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jcp]
TABLE 2. Immunohistochemical staining for PML protein in soft tissue sarcoma
PML complete loss (%) PML focal positivity (%) PML diffuse positivity (%)
Synovial sarcoma (25 samples) 16 (64) 9 (36) 0
Myoﬁbroblastic sarcoma (13 samples) 5 (38.5) 6 (46.1) 2 (15.4)
Liposarcoma (34 samples) 14 (41.2) 15 (44.1) 5 (14.7)
Myxoid (12 samples) 7 (58.3 5 (41.7) 0
Dedifferentiated (8 samples) 5 (62.5) 2 (25) 1 (12.5)
Pleomorphic (14 samples) 3 (21.4) 6 (42.9) 5 (35.7)
Pleomorphic sarcoma (15 samples) 4 (26.7) 6 (40) 5 (33.3)
Leiomyosarcoma (15 samples) 6 (40) 7 (46.7) 2 (13.3)
Angiosarcoma (9 samples) 5 (55.6) 4 (44.4) 0
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Regarding the correlation between PML
immunohistochemical expression and radiologic response to
therapy, a CT scan after the third cycle of treatment in patients
with complete PML loss showed complete response in 4.6% of
all cases, partial response in 32.6%, stable disease in 37.2%, and
progression of disease in 25.6%. In patients with a partial loss of
PML expression we observed a partial response in 23.5% of
cases, stable disease in 45.6%, and progression of disease in
30.9%, with no complete responses among these patients.
All these data have been reported in Table 4.
Discussion
Although PML oncosuppressive role was hypothesized since its
identiﬁcation at the breakpoint of t(15;17) translocation,
growing evidences in literature are today conﬁrming it. Given
its multiple interactions in the context of PML-NBs, allowed by
PML post-traslational modiﬁcations especially lysine
SUMOylation in three different sites, PML seems to play a
crucial role in the control of apoptosis, cellular proliferation and
senescence, and protein synthesis.
PML involvement in apoptosis regulation emergedwith a ﬁrst
study by Wang et al. (1998) which analyzed the survival of PML
wild type and PML knocked-down mice and the viability of
splenocytes after g-irradiation. PML/ mice were protected
from g-irradiation-induced death compared with Pmlþ/þmice
(P< 0.02) and apoptosis in their splenocytes was signiﬁcantly
lower, conﬁrming PML requirement in DNA-damage-induced
apoptosis. Although the mechanisms through which PML
regulates apoptosis are not completely clear yet, the
interactions with p53, DAXX, and c-Jun seem to be particularly
relevant. PML has been proven to regulate p53 stability, by
interfering with Mdm2 ubiquitination (Kurki et al., 2003),
activity by regulating acetylation (Halazonetis et al., 2008),
and its capability to induce the transcription of apoptosis
intermediaries by increasing HIPK2-mediated p53
phosphorylation (Moller et al., 2003). The interaction between
PML and DAXX causes a cellular sensitization to Fas-induced
apoptosis (Torii et al., 1999) and blocks the nuclear
transcriptional repression usually induced by DAXX (Li et al.,
2000). Finally, PML has been found to modulate c-Jun
proapoptotic function by activating JNK-dependent
phosphorylation (Salomoni et al., 2005).
Different studies have recently underlined how PML
overexpression leads to a cell cycle arrest, mainly in G1 phase
(Le et al., 1996; Mu et al., 1997). Cellular senescence, meant as a
permanent exclusion by cellular cycle, is regulated by PML
through its interactions with p53 (as previously reported) and
pRB (Wang et al., 1998), whose levels are increased by PML
overexpression (Ferbeyre et al., 2000; Gurrieri et al., 2004) and
whose repressive function results strengthened (through a
HDAC-mediated mechanism; Mallette et al., 2004).
Interestingly, PML seems to be also involved in the control of
protein synthesis, by causing a nuclear retention of the
eukaryotic translation initiation factor eIF4E (Cohen et al.,
2001; Culjkovic et al., 2007), and angiogenesis, by modulating
hypoxia inducible factor a levels through the mTOR pathway
(Bernardi et al., 2006).
Despite these emerging evidences, few studies analyzed PML
role in human tumors. Gurrieri et al. evaluated PML IHC
expression in different histological subtypes of human neoplasia
and detected a reduced or abolished PML expression in
prostate adenocarcinomas (63% and 28%, respectively), colon
adenocarcinomas (31% and 17%), breast carcinomas (21% and
31%), lung carcinomas (36% and 21%), lymphomas (14% and
69%), CNS tumors (24% and 49%), and germ cell tumors
(36% and 48%), but not in thyroid or adrenal carcinomas.
TABLE 3. PML down-regulation inﬂuence on TTP, duration of response
and OS in locally advanced and metastatic soft tissue sarcoma
TTP
Median TTP
(95% CI) in months P-value
PML expression complete loss 3.50 (95% CI: 1.78–4.93) <0.0001
PML expression partial loss 7.00 (95% CI: 3.51–12.11)
Duration of response
Median duration of response
(95% CI) in months
PML expression complete loss 1.8 (95% CI: 1.01–5.80) 0.007
PML expression partial loss 7.5 (95% CI: 4.33–10.34)
OS Median OS (95% CI) in months
PML expression complete loss 9.80 (95% CI: 5.67–18.80) 0.02
PML expression partial loss 17.50 (95% CI: 11.50–23.30)
Fig. 2. Kaplan–Meiersurvival curves forsoft tissuesarcomapatients,accordingtoPMLimmunohistochemicalexpression.PMLdown-regulation
in soft tissue sarcoma specimens was associated with a statistically signiﬁcantly lower progression-free survival (P<0.0001) and overall survival
(PU 0.02). [Color ﬁgure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jcp]
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Furthermore, the authors underlined how PML loss was also
associated with tumor progression in prostate
adenocarcinomas (progression from prostatic intraepithelial
neoplasia to invasive carcinoma was associated with complete
PML loss; P< 0.001), breast cancer (complete PML loss was
associated with lymph node metastasis; P¼ 0.01), and CNS
tumors (complete PML loss was associated with high-grade
tumors; P¼ 0.003; Gurrieri et al., 2004). PML IHC expression
has been found to be reduced or abolished also in a minority of
gastric carcinomas (31.7% and 10.6%, respectively) and its
complete loss resulted associated with more lymphatic
invasion, higher pTNM stage, and worse patients survival (Lee
et al., 2007). Finally, a study from our group evaluated PML
expression in ampullary carcinoma: in 38.7% of the specimens,
PML was classiﬁed as absent, in 25.8% as focally expressed, and
in 22 35.5% as diffusely expressed. Furthermore, disease-free
survival (DFS) and OS were signiﬁcantly inﬂuenced by PML
expression (P¼ 0.001 and P¼ 0.002, respectively). By a
multivariate analysis, PML expression was the strongest
prognostic factor for DFS (P¼ 0.003) and the only statically
signiﬁcant prognostic factor for OS (P¼ 0.009) (Vincenzi et al.,
2009).
PML possible role in sarcomatous transformation has
been postulated by Huang et al. (2008), through the study
of chromosomal aberrations in malignant diffuse-type
tenosynovial giant cell tumors (D-TSGCTs). In fact the deletion
at 15q, the locus containing PML gene, represented the most
frequent non-random chromosomal alteration in malignant D-
TSGCTs (Huang et al., 2008). Up to date, few is known about
PML expression in soft tissue sarcoma and no predictive factors
are available at the moment in order to select those patients
who could beneﬁt from a standard ﬁrst line chemotherapy
or those who need a different approach. Single agents
(doxorubicin, ifosfamide, dacarbazine) and anthracycline-based
combination regimens (doxorubicin or epirubicin with
ifosfamide and/or dacarbazine) have been widely used in the
metastatic stage and today epirubicin (30mg/m2 day 1–3)/
ifosfamide (3,000mg/m2 day 1–3)/mesna (3,000mg/m2 day 1–3)
represents a valid possible ﬁrst line therapy in this setting,
according to NCCN guidelines.
A previous smaller study from our group (Vincenzi et al.,
2010) has already pointed out how PML expression was
signiﬁcantly down-regulated in soft tissue sarcoma. The present
study assessed PML immunohistochemical expression in a
wider popolation (111 cases of synovial sarcoma,
myoﬁbroblastic sarcoma, angiosarcoma, liposarcoma,
leiomyosarcoma, and pleomorphic sarcoma) and evaluated, for
the ﬁrst time, the possible role of PML down-regulation as a
factor predicting resistance to alkylating agents/anthracycline-
based ﬁrst line therapy in patients affected by locally advanced
and metastatic soft tissue sarcoma. The results underline how
PML down-regulation represents a common occurrence in
soft tissue sarcoma different histotypes, suggesting a possible
pathogenetic role of the gene itself in the tumorigenesis of these
complex tumors. In concordance with previous studies, PML
immunohistochemical expression was found to be partially
or completely loss in some histotypes of soft tissue sarcoma
(synovial sarcoma, myoﬁbroblastic sarcoma, angiosarcoma,
myxoid, and dedifferentiated liposarcoma, leiomyosarcoma)
but not in other (pleomorphic sarcoma and pleomorphic
liposarcoma). Themost signiﬁcative results have been obtained
by comparing PML expression in angiosarcoma and synovial
sarcoma specimenswith the normal tissue samples.Of interest,
the expression of PML protein was found to be different among
the three subtypes of liposarcoma analysed: it resulted
extremely reduced in dedifferentiated and myxoid liposarcoma
but not in the plemorphic, pointing out once more how
liposarcoma subtypes (pleomorphic, dedifferentiated, and
myxoid) should be considered as different pathological entities.
The preliminary data concerning PML predictive value in
patients treated with alkylating/anthracycline-based ﬁrst line
therapy proved to be interesting as well. In those patients with
PML quantitative down-regulation, a worse outcome was
revealed in terms of TTP and duration of response, conﬁrming
PML value as a factor predicting resistance to standard
alkylating/anthracycline-based ﬁrst line therapy. Given the
statistically signiﬁcant difference obtained in terms of OS
between patients with a partial or complete loss of PML
expression (9.8 months) and those whose expression was
preserved (17.5 months), it is reasonable postulate a possible
prognostic signiﬁcance of PML in patients affected by soft tissue
sarcoma, as also suggested by previous studies. On the
contrary, it does not seem to be any signiﬁcant correlation
between PML expression and the radiologic evaluation of the
treatment response throughout RECIST criteria.
Despite the relevance of the data previously reported, the
present study validity is limited by its retrospective nature and
the small sample size. Moreover, it is clear today that the term
‘‘soft tissue sarcomas’’ includes several different entities, that
have been proven to be characterized by a different biological
behavior, prognosis, and treatment approach: therefore, PML
value as a prognostic and predictive factor should be assessed
apart in the different sarcoma subtypes, starting from the most
frequent ones (such as synovial sarcoma, leiomyosarcomas, and
liposarcomas). Further studies are needed to conﬁrm these
results, to corroborate PML signiﬁcance as a prognostic factor
and to prospectically evaluate PML predictive value in the
different sarcoma histotypes.
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